415 Investments
415 Investments is a company.
Active
Updated: ·
About
415 Investments is a company.
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at 415 Investments.
415 Investments is a company.
415 Investments is a company.
Key people at 415 Investments.
Key people at 415 Investments.
# 415 Capital: High-Level Overview
415 Capital is a specialist venture capital firm headquartered in Munich, Germany, dedicated to investing in breakthrough medical device and therapeutic innovations.[2][4] The firm operates as a MedTech-focused venture investor with a mission to back life-saving medical innovations while generating returns for investors. With nearly $200 million in assets under management, 415 Capital has established itself as a key player in European and transatlantic medical technology investing.[2]
The firm's investment philosophy centers on clinical-stage MedTech companies across cardiovascular, neurovascular, neuromodulation, medical robotics, and AI-enabled medical technologies.[2] Since launching its first institutional fund in 2020, 415 Capital has deployed capital into more than 50 MedTech startups, whose technologies now help physicians treat hundreds of thousands of patients annually.[2] The firm recently expanded its impact with a €150 million second fund, demonstrating strong investor confidence in its track record.[2]
415 Capital launched its first institutional fund in 2020, establishing itself as a dedicated MedTech venture investor during a period of accelerating digital health and medical device innovation.[2] The firm's founding reflected a strategic focus on the European MedTech ecosystem, particularly in Germany and surrounding regions, while also maintaining investment reach into the U.S. and Israel.[2]
The firm's early success built momentum quickly: within five years, its portfolio companies attracted more than €600 million ($650 million) in follow-on financing from top-tier life science venture capital firms and corporate strategic investors.[2] This validation from peer investors and strategic acquirers underscored the quality of 415 Capital's deal sourcing and company selection.
415 Capital operates at the intersection of several powerful trends: the aging global population driving demand for innovative cardiovascular and neurological treatments, the digitalization of healthcare enabling AI-powered monitoring and diagnostics, and the maturation of European MedTech ecosystems as alternatives to Silicon Valley-dominated venture investing.[2]
The firm's focus on clinical-stage companies positions it upstream of traditional corporate venture and late-stage investors, capturing value creation during the critical transition from proof-of-concept to regulatory approval and early commercialization. By concentrating on breakthrough innovations in high-burden disease areas like cardiovascular and neurovascular disease, 415 Capital aligns financial returns with measurable patient impact—a positioning that resonates with institutional LPs increasingly focused on impact investing.[2]
The firm's success in attracting follow-on capital from top-tier investors signals that European MedTech startups can compete globally for institutional capital, potentially shifting some venture activity away from traditional U.S.-centric hubs.
415 Capital is well-positioned to capitalize on sustained demand for medical innovation in aging societies and the growing acceptance of European MedTech as a credible alternative to U.S.-dominated venture ecosystems. The €150 million second fund signals confidence in the firm's model and suggests it will continue expanding its portfolio in cardiovascular, neurovascular, and AI-enabled medical technologies.
The firm's future influence will likely depend on its ability to scale operational support for portfolio companies entering regulatory and commercialization phases, and on whether its portfolio companies can achieve meaningful exits—either through acquisition by larger medical device companies or public markets. As healthcare systems worldwide prioritize cost-effective innovation and digital health integration, 415 Capital's focus on clinical validation and real-world patient impact positions it as a trusted partner in translating breakthrough science into healthcare solutions that matter.
